Comparison of the efficacy of single or double intravesical epirubicin instillation in the early postoperative period to prevent recurrences in non-muscle-invasive urothelial carcinoma of the bladder: prospective, randomized multicenter study.

Abstract

OBJECTIVES:

To investigate the efficacy of single or double epirubicin instillation during the early postoperative period (EPP) in intermediate-risk non-muscle-invasive urothelial cancer.

METHODS:

Patients with primary and solitary or multiple (3 or less) Ta (grade 2-3) or T1 (grade 1-2) tumors were enrolled. Patients were randomized to receive either a single dose of 100 mg epirubicin instillation within 6 h or a second 100 mg epirubicin instillation during the 12th-18th hours after a complete TUR-BT. At the end of the 60-month follow-up period, the available data were statistically analyzed. The end-points of the study were determined as disease-free survival, progression and recurrence rates, time to recurrence, and time to progression.

RESULTS:

A total of 299 patients from 24 institutions were randomized between January 2002 and June 2004. There were 143 patients from 18 institutions who met the eligibility criteria. The follow-up and disease-free survival periods were 16.9 months and 16 months, respectively. There was no statistical difference in the demographic properties and the end-points between the groups.

CONCLUSIONS:

A single dose of intravesical 100 mg epirubicin chemotherapy during the early postoperative period for primary intermediate-risk non-muscle-invasive urothelial cancer achieved 16 months of mean disease-free survival. A second intravesical epirubicin instillation did not provide any significant benefit.

• Authors: Levent Türkeri, Yılören Tanıdır, Çağ Çal, Haluk Özen, Hayrettin Şahin, Turkish Urooncology Society
• Journal: Urologia internationalis (Urol Int) Vol. 85 Issue 3 Pg. 261-5 ( 2010) ISSN: 1423-0399 [Electronic] Switzerland
• PMID: 20332605 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
• Copyright: Copyright © 2010 S. Karger AG, Basel.

Chemical References

• Antibiotics, Antineoplastic
• Epirubicin

Topics

• Administration, Intravesical
• Aged
• Antibiotics, Antineoplastic (therapeutic use)
• Carcinoma (drug therapy, prevention & control)
• Disease-Free Survival
• Epirubicin (therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Postoperative Period
• Recurrence
• Treatment Outcome
• Urinary Bladder Neoplasms (drug therapy, prevention & control)
• Urothelium (pathology)